Antibodies against HPVP and citrullinated HPVP were detected by ELISA in the sera of 101 patients with early-stage RA, 149 patients with other
rheumatic diseases and 40 healthy controls. The prevalence and diagnostic values of these
antibodies for early-stage RA were analyzed by statistical software.
RESULTS: (1)The prevalence of
IgG,
IgM antibodies to citrullinated HPVP in early-stage RA were significantly higher than that in the patients with other
rheumatic diseases as well as in the healthy individuals.(2)The diagnostic sensitivity of
IgG and
IgM citrullinated HPVP
antibodies in early-stage RA were 62.4% and 66.3% respectively and the specificity value of the two antibody isotypes were 88.7% and 89.6%,similar to that of the
anti-CCP antibody. (3)The positivity rates of
IgG and
IgM antibodies against citrullinated HPVP were 59.4% and 71.9% in
IgM-RF negative early-stage RA patients, and 39.4% and 51.5% in
anti-CCP antibody negative early-stage RA patients. (4) The DAS28 score [
IgG (6.3±1.0) vs. (5.6±0.9), P=0.002;
IgM (6.2±1.1) vs. (5.6±0.8), P=0.008] , X-ray stages (
IgG 56.1% vs. 21.2%, P=0.001;
IgM 50.9% vs. 29.4%, P=0.036),
anti-CCP antibodies(
IgG 96.8% vs. 55.3%, P=0.001;
IgM 89.6% vs. 64.7%, P=0.023) in citrullinated HPVPP positive patients were higher than those of citrullinated HPVP negative patients. Additionally, the levels of ESR[
IgG(70.3±32.4)vs.(51.9±27.8), P=0.004;
IgM (67.4±31.5)vs.(53.8±27.7), P=0.035] in citrullinated HPVP positive patients were higher than those of negative patients (P<0.05).
CONCLUSION: